Prolactin ELISA

The DRG Prolactin ELISA is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of Prolactin in serum.

Regulatery Status: RUO
Catalog No Size
Product Catalog No: EIA-1291 Pack Size: 96 Wells

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Summary

Human prolactin (lactogenic hormone) is secreted from the anterior pituitary gland in both men and women (1). Human prolactin is a single chain polypeptide hormone with a molecular weight of approximately 23.000 daltons (2). The release and synthesis of prolactin is under neuroendocrinal control, primarily through Prolactin Releasing Factor and Prolactin Inhibiting Factor (3).

Women normally have slightly higher basal prolactin levels than men; apparently, there is an estrogen- related rise at puberty and a corresponding decrease at menopause. The primary functions of prolactin are to initiate breast development and to maintain lactation. Prolactin also suppresses gonadal function (4,5). During pregnancy, prolactin levels increase progressively to between 10 and 20 times normal values, declining to nonpregnant levels by 3-4 weeks post

– partum (4). Breast feeding mothers maintain high levels of prolactin, and it may take several months for serum concentrations to return to non-pregnant levels (3,4). The determination of prolactin concentration is helpful in diagnosing hypothalamic- pituitary disorders (3,4).

Microadenomas (small pituitary tumors) may cause hyperprolactinemia, which is sometimes associated with male impotence (6). High prolactin levels are commonly associated with galactorrhea and amenorrhea. Prolactin concentrations have been shown to be increased by estrogens, thyrotropin- releasing hormone (TRH), and several drugs affecting dopaminergic mechanisms (7,8,9,10). Prolactin levels are elevated in renal disease and hypothyroidism, and in some situations of stress, exercise, and hypoglycemia. Additionally, the release of prolactin is episodic and demonstrates diurnal variation (11). Mildly elevated prolactin concentrations should be evaluated taking these considerations into account. Prolactin concentrations may also be increased by drugs such as chloropromazine and reserpine, and may be lowered by bromocyptine and L-dopa (12).

The DRG Prolactin ELISA provides a rapid, sensitive, and a reliable assay. The antibodies developed for the test will determine a minimal concentration of human prolactin of 0.35 ng/mL. There is no cross-reactivity with hCG, TSH, LH, FSH, or hGH.

Test Principle

The DRG Prolactin ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle.

The microtiter wells are coated with a monoclonal [mouse] antibody directed towards a unique antigenic site on a Prolactin molecule. An aliquot of patient sample containing endogenous Prolactin is incubated in the coated well with enzyme conjugate, which is an anti- Prolactin antibody conjugated with horseradish peroxidase. After incubation the unbound conjugate is washed off.

The amount of bound peroxidase is proportional to the concentration of Prolactin in the sample.

Having added the substrate solution, the intensity of colour developed is proportional to the concentration of Prolactin in the patient sample.

Order Enquiry

    Order Enquiry Form

    References
    • Shome, B. and Parlow, A.F., J. Clin. Endocrinol. Metab., 45, 1112-1115, (1977).
    • Niall, M.D. et al, “The Chemistry of Growth Hormone and the Lactogenic Hormones”; Recent Progr. Horm. Res. 29, 471 (1974)
    • Friesen, H. and Hwang, P., Ann. Rev. Medecine, 24, 251-270, (1973)
    • Cowden, E.A., Ratcliffe, W.A., Beastall, G.H., and Ratcliffe, J.G., Annals Clin. Biochem., 16, 113-121, (1979).
    • Frantz, A.G., N. Engl. J. Med., 298, 201-207 (1978)
    • Thorner, M.O., Edwards, C.R.W., Hanker, J.P., Abraham, G., and Besser, G.M., “The Testes in Normal and Infertile Men”, Troen, P. and Nankin, H.R. (eds.), Raven Press, New York, 351-366, (1977).
    • Daughday, W.H., “The Adenohypophusis, Textbook of Endocrinology”; Williams, 6th Ed., Chapter 3, 87-87, (1981)
    • Tyson, J.E., Hwang, P., Guyela, H. Friesen, H.G., Am. J. Obsted. Gynecol. 113, 14-20, (1972).
    • Aubert, M.l., Grumbach, M.M. and Kaplan, S.L., Acta Endocrin. 77, 460-476 (1974)
    • Jacobs, L., Snyder, P., Wilber, J., Utiger, R., and Daughday, W., J. Clin. Endocrin. 33, 996, (1978).
    Documents
    Enquiry